The Cancer Calculus, coordinated by the International Consortium of Investigative Journalists with Deutsche Welle and 46 ...

Some of the philanthropic foundations that fund ICIJ have programs or campaigns advocating for reform of the pharmaceutical ...

Merck (NYSE:MRK) received expanded EU approval for KEYTRUDA-based regimens in platinum-resistant ovarian cancer, making it ...

Once a company product is delivered through the legitimate supply chain to a distributor, the company does not have ...

First approved by the US FDA in 2014 for advanced skin cancer, Keytruda is now used globally for certain lung cancers, ...

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming ...

India Keytruda cancer drug scam exposes counterfeit vials sold to desperate patients, probe reveals hospital insiders, black ...

In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...

Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s ...

Two stocks retirement investors typically reach for in uncertain markets have risen notably in recent months. Is it too late to buy?